Bharat Biotech to ramp up production of Covaxin to 100-120 mn doses by July

There has been shortage of vaccines after it was decided to open up vaccination to all those above 18 years.

Covaxin
Photo: Bloomberg
ANI General News
2 min read Last Updated : May 31 2021 | 6:32 PM IST

With ramping up of production capacities, nearly 25 crore 'Made in India' vaccines are expected to be available by August, a senior official has said and noted that it will go a long way in meeting the target of vaccinating one crore people daily against COVID-19.

There has been shortage of vaccines after it was decided to open up vaccination to all those above 18 years.

"Yesterday, SII in a letter mentioned that they will be manufacturing 10-12 crore of vaccine doses, which is almost 50 per cent ramping up (of their capacity) by June-end. Similarly, Covaxin is also going to increase its production and by July-end they will also produce between 10-12 crore doses (per month)," said Dr N K Arora, Chairman of COVID-19 working group under National Technical Advisory Group on Immunization (NTAGI).

Pune-based SII (Serum Institute of India) manufactures Covishield vaccine against COVID-19 while Hyderabad-based Bharat Biotech manufactures Covaxin.

"By August we will have 20-25 crore vaccine doses per month, another 5-6 crore doses from other manufacturing units or if we get international vaccine doses. The objective is to vaccinate one crore people every day," Dr Arora said.

He said India may start in few weeks testing the feasibility of a regimen "that mixes two different doses of COVID vaccines to see if it helps boost the immune response to virus". The researchers in such a study would see the effects of giving a different vaccine in the second dose.

At present, the country has availability of 7-7.5 crore doses of Covishield and Covaxin per month.

India's daily COVID-19 cases continue to decline and 1,52,734 new infections were recorded in the last 24 hours, the lowest in 46 days.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusBharat BiotechCoronavirus Vaccine

First Published: May 31 2021 | 6:24 PM IST

Next Story